ARTICLE | Company News
The university granted Fortress’ newly formed Caelum Biosciences Inc. subsidiary exclusive, worldwide development and commercialization rights to CAEL-101. The chimeric fibril-reactive mAb is in Phase...
The university granted Fortress’ newly formed Caelum Biosciences Inc. subsidiary exclusive, worldwide development and commercialization rights to CAEL-101. The chimeric fibril-reactive mAb is in Phase...